Retrospective cohort study of Huashi Baidu granules in the treatment of mild COVID-19

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2200006037

Enrollment

Unknown

Registered

2022-05-26

Start date

2022-05-25

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Routine health guidance combined with Huashi Baidu granules group:Nil

Routine health guidance group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: It conforms to the mild diagnosis of COVID-19 in the Novel Coronavirus Diagnosis and Treatment Protocol for Pneumonia Infection (Trial Version 9) released by the National Health Commission. The novel Coronavirus nucleic acid test confirmed the mild clinical symptoms, including low fever, slight fatigue, olfactory and gustatory impairment.

Exclusion criteria

Exclusion criteria: Asymptomatic infected persons; Patients with serious primary diseases of cardio-cerebrovascular, lung, kidney and hematopoietic system; Pregnant or lactating women; History of allergy to prescribed drugs.

Design outcomes

Primary

Measure	Time frame
Time of first negative nucleic acid conversion;length of hospitalization;	—

Countries

China

Contacts

Public ContactHongze Wu

yihuihn@163.com18970256865

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026